New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:21 EDTICPTIntercept price target raised to $493 from $449 at Wedbush
Wedbush raised its price target for Intercept Pharmaceuticals shares to $493 saying a new Phase 2 clinical study for OCA in alcoholic hepatitis increases the company's acquisition value. The firm reiterates an Outperform rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:53 EDTICPTIntercept initiated with a Buy, $465 target at UBS
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.
April 13, 2015
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information
April 9, 2015
08:20 EDTICPTWedbush reiterates $493/share acquisition value for Intercept
Subscribe for More Information
April 8, 2015
06:57 EDTICPTIntercept added to short-term buy list at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use